Lymphoma Refereces

This page lists publications that have been referenced by our Specialists during a session.

1) ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. Ralph M. Meyer, Mary K. Gospodarowicz, Joseph M. Connors, Robert G. Pearcey, Woodrow A. Wells, Jane N. Winter, Sandra J. Horning, A. Rashid Dar, Chaim Shustik, Douglas A. Stewart, Michael Crump, Marina S. Djurfeldt, Bingshu E. Chen, Lois E. Shepherd. New England Journal of Medicine. 2012; 366:399-408.

2) The Case for Combined-Modality Therapy for Limited-Stage Hodgkin's Disease. Hill-Kayser, Christine E.; Plastaras, John P.; Tochner, Zelig; Glatstein, Eli.  The Oncologist. 2012; 17(8): 1006.

3) Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma. Thomas P. Miller,Steve Dahlberg, Robert Cassady, David J. Adelstein, Catherine M. Spier, Thomas M. Grogan, Michael LeBlanc, Susan Carlin, Ellen Chase, Richard I. Fisher. New England Journal of Medicine. 1998; 339:21-26.

4)  Combined-Modality Therapy for Early-Stage Hodgkin Lymphoma: Maintaining High Cure Rates While Minimizing Risks.
Chris R. Kelsey, MD , Anne W. Beaven, MD , Louis F. Diehl, MD , Leonard R. Prosnitz, MD. Oncology. 2012; 26(12): 1-13.

5) Comparative Risk-adjusted Mortality Outcomes After Primary Surgery, Radiotherapy, or Androgen-deprivation Therapy for Localized Prostate Cancer. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Cancer. 2010; 116(22):5226-34. Erratum in: Cancer. 2011;117(12):2825.

6) Dose-Intensification in Early Unfavorable Hodgkin’s Lymphoma: Final Analysis of the German Hodgkin Study
Group HD14 Trial. Bastian von Tresckow, Annette Plu¨tschow, Michael Fuchs, Beate Klimm, Jana Markova, Andreas Lohri,
Zdenek Kral, Richard Greil, Max S. Topp, Julia Meissner, Jose´e M. Zijlstra, Martin Soekler, Harald Stein,
Hans T. Eich, Rolf P. Mueller, Volker Diehl, Peter Borchmann, and Andreas Engert. Journal of Clinical Oncology. 2012; 30(9): 907-13.

7)  Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. K. J. Savage, N. Al-Rajhi, N. Voss, C. Paltiel, R. Klasa, R. D. Gascoyne & J. M. Connors.  2006; Annals of Oncology. 17: 123–130.

8) High Response Rates and Lasting Remissions After Low-Dose Involved Field Radiotherapy in Indolent Lymphomas. Haas, RLM, Poortmans, D de Jong, Aleman, BMP, et al. Journal of Clinical Oncology. 2003; 21(13):2474-2480.

9) Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsey CR. International Journal of Radiation Oncololgy Biology Physics. 2012;84(3):762-7.

10) Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma.
Monfardini S, Banfi A, Bonadonna G, Rilke F, Milani F, Valagussa P, Lattuada A. International Journal of Radiation Oncology Biology Physics. 1980;6(2):125-34.

11) Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients with Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial. Eich, HT, Volker, D, Gorgen, H, et. al. Journal of Clinical Oncology. 2010; 28(27):4199-4206.

12) Intensity-modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and  Disease Control in Localized Prostate Cancer. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, Holmes JA, Reeve BB, Godley PA, Carpenter, WR, Chen RC. JAMA. 2012;307(15):1611-20.

13) International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. Alberto Biggi, Andrea Gallamini, Stephane Chauvie, Martin Hutchings, Lale Kostakoglu, Michele Gregianin, Michel Meignan, Bogdan Malkowski, Michael S. Hofman, and Sally F. Barrington. The Journal of Nuclear Medicine. 2013; 54(5): 683-90.

14) Involved-Nodal Radiation Therapy as a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size. Campbell, BA, Voss, N, Pickles, T, et al.  Journal of Clinical Oncology. 2008; 26(32):5170-5174.

15) Involved-node Radiotherapy (INRT) in Patients with Early Hodgkin Lymphoma: Concepts and Guidelines. Girinsky, T, Var der Maazen, R, Specht, L, et al. Radiotherapy and Oncology. 2006;79(3):270-7.

16) Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. J. Shustik, M. Quinn, J. M. Connors, R. D. Gascoyne, B. Skinnider, L. H. Sehn. Annals of Oncology. 2011; 22: 1164–1169.

17) Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Abbreviated Systemic Therapy and Consolidation Radiotherapy: Involved-Field Versus Involved-Node Radiotherapy. Campbell, BA, Connors, JM, Gascoyne, RD, Morris, WJ, Pickles, T, Sehn, LH. Cancer.2012;118(17):4156-65.

18) Long-Term Outcomes for Patients With Limited Stage Follicular Lymphoma: Involved Regional Radiotherapy Versus Involved Node Radiotherapy. Campbell, BA, FRANZCR, Voss, N, FRCPC, FRCR, Wood, R, Cancer.2010;116(16):3797-806.

19) Low-Dose Involved-Field Radiotherapy as Alternative Treatment of Nodular Lymphocyte Predominance Hodgkin's Lymphoma. Rick L.M. Haas, Theo Girinsky, Berthe M.P. Aleman, Michel Henry-Amar, et al. International Journal of Radiation Oncology Biology Physics. 2009;74(4): 1199-1202.

20) Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas. Karen J. Neelis, Erik C. Schimmel, Maarten H. Vermeer, Nancy J. Senff, et al. International Journal of Radiation Oncology Biology Physics. 2009; (74)1: 154-158.

21) Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). Lena Specht, Joachim Yahalom, Tim Illidge, Anne Kiil Berthelsen, Louis S. Constine, Hans Theodor Eich, Theodore Girinsky, Richard T. Hoppe, Peter Mauch, George Mikhaeel, Andrea Ng. International Journal of Radiation Oncology Biology Physics. 2013; Article in Press.

22) Pathogenesis and Treatment of Extranodal Natural Killer/T-Cell Lymphoma. Suzuki, R. Seminars in Hematology. 2014;51(1): 42-51.

23) Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. G. Martinelli. G. Ryan, J. F. Seymour, L. Nassi, S. Steffanoni, A. Alietti, L. Calabrese, G. Pruneri, L. Santoro, M. Kuper-Homme, R. Tsang, P. L. Zinzani, A. Taghian, E. Zucca, F. Cavalli.  Annals of Oncology. 2009; 20: 1993–1999.

24) Primary Gastric Lymphoma: Brief Overview of the Recent Princess Margaret Hospital Experience. Gospodarowiez, MK, Pintilie, M, Tsang, R, et al. Recent Results in Cancer Research. 2000;156:108-15.

25) Primary Mediastinal Large B-Cell Lymphoma. Kerry J. Savage. The Oncologist. 2006;11:488–495.

26) Prospective Study of the Efficacy of Breast Magnetic Resonance Imaging and Mammographic Screening in Survivors of Hodgkin Lymphoma. Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Robyn L. Birdwell, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus and Peter M. Mauch. Journal of Clinical Oncology. 2013; published online April 22, 2013.

27) Radiation Dose Selection in Hodgkin's Disease Patient's with Large Mediastinal Adenopathy Treated with Combined Modality Therapy. Elconin, JH, Roberts, KB, Rizzieri, DA, et al.  International Journal of Radiation Oncology Biology Physics. 2000;48(4):1097-1105.

28) Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO–EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers. Nancy J. Senff, Juliette J. Hoefnagel, Patty M. Jansen, Maarten H. Vermeer, Joop van Baarlen, Willeke A. Blokx, Marijke R. Canninga-van Dijk, Marie-Louise Geerts, Konnie M. Hebeda, Philip M. Kluin, King H. Lam, Chris J.L.M. Meijer, and Rein Willemze. Journal of Clinical Oncology. 2007; 25(12): 1581-7.

29) Recommendations for the Use of Radiotherapy in Nodal Lymphoma. P.J. Hoskin, P. Díez, M. Williams, H. Lucraft, M. Bayne. Clinical Oncology. 2013; 25: 49-58.

30) Reduced Dose Radiotherapy for Local Control in Non-Hodgkin Lymphoma: a Randomized Phase III Trial. Lowry L, Smith, LL, Qian, P, Falk, W, Benstead, S, Illidge, K, Linch, T, Robinson, D, Jack, MA, Hoskin, P. Radiotherapy & Oncology. 2011;100(1):86-92.

31) Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. Engert, A, Plutschow, A, Eich, HT, et al. New England Journal of Medicine. 2010;363(7):640-52.

32) Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. Vassilakopoulos, T, Pangalis, G, Katsigiannis, A, Papageorgiou, S, Constantinou, N, et al. The Oncologist. 2012; 17:239 –249.

33) Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. Elena M. van Leeuwen-Segarceanu, Willem-Jan W. Bos, Lucille D.A. Dorresteijn, Benno J.W.M. Rensing, Jan A.S. van der Heyden, Oscar J.M. Vogels, Douwe H. Biesma. Cancer Treatment Reviews. 2011; 37: 391–403.

34) Scrotal Irradiation in Primary Testicular Lymphoma: Review of the Literature and In Silico Planning Comparative Study. Charlotte L. Brouwer, Esther M. Wiesendanger, Peter C. van der Hulst, Gustaaf W. van Imhoff, Johannes A. Langendijk, Max Beijert. International Journal of Radiation Oncology Biology Physics. 2013;85(2): 298-308.